This document describes a study investigating the role of the protein Morgana in breast cancer metastasis. The study found that knocking down Morgana impaired migration, invasion, and metastasis of breast cancer cells in vitro and in vivo. Mechanistically, Morgana was found to increase the transcriptional activity of NF-κB, leading to increased expression of metastasis-promoting genes like MMP-9. Overexpressing Morgana had the opposite effect of increasing NF-κB target gene expression. Therefore, Morgana appears to promote breast cancer metastasis by activating the NF-κB pathway and increasing expression of pro-metastatic genes.
1. The study found that ADAM8, a protein highly expressed in triple-negative breast cancers, regulates the expression of miRNAs, including miR-720.
2. Experiments showed that ADAM8 induces miR-720 expression via activation of the β1-integrin/ERK signaling pathway.
3. Modulating miR-720 levels in triple-negative breast cancer cells revealed that miR-720 promotes migratory and invasive abilities, suggesting it plays a role in the aggressive phenotype driven by ADAM8.
This document summarizes a study investigating the role of microRNA-122 (miR-122) in regulating intrahepatic metastasis of hepatocellular carcinoma (HCC). The study found that miR-122 expression is significantly downregulated in HCC tumors with intrahepatic metastasis. Restoring miR-122 expression in metastatic HCC cell lines reduced in vitro migration, invasion, and tumor growth in vivo. Computational analysis identified multiple target genes of miR-122, including ADAM17, which was shown to be involved in metastasis. Silencing ADAM17 had similar effects as restoring miR-122, reducing in vitro and in vivo measures of metastasis. The study suggests that miR-122 acts as a tumor suppressor
This study investigated the association between the MMP-3 promoter polymorphism (-1171 5A->6A) and risk of oral submucous fibrosis (OSMF) and head and neck squamous cell carcinoma (HNSCC) in an Indian population. The authors genotyped 362 subjects, including 101 OSMF cases, 135 HNSCC cases, and 126 healthy controls. They found the 5A allele frequency was higher in OSMF (0.15) and HNSCC (0.13) compared to controls (0.07). Statistical analysis revealed a significant difference in 5A genotype frequency between OSMF and controls (p=0.01, OR=2.26) and between HNSCC
This document summarizes a study investigating the role of microRNA-302 in regulating retinal epithelial cell fate by targeting the TGF-β type II receptor. The study demonstrates that microRNA-302 promotes pluripotency in ARPE cells in vitro by regulating TGF-β signaling and epigenetic changes. It also shows that small molecules DZNEP and SB431542 can induce pluripotency by attenuating pathways involved in cell differentiation, supporting the potential for microRNAs and small molecules in regenerative medicine and therapeutics for diseases like diabetic retinopathy.
This study analyzed 264 gastric cancers for mutations in exons 9 and 20 of the PIK3CA gene. PIK3CA mutations were found in 42 cases (16%), all heterozygous missense mutations. The most common mutation was H1047R in exon 20 (62% of mutations) and the second most common was Q546K in exon 9 (9.5% of mutations). A meta-analysis of 27 publications found that the ratio of exon 20 to exon 9 mutations varied by cancer type, being highest in gastric cancer. The exon mutation selectivity is a signature of the cancer type.
miRNA Breast Cancer Prognosis -- Ingenuity SystemsNatalie Ng
1) The document describes research to develop microRNA prognostic signatures that can predict breast cancer metastasis and determine which patients would benefit from chemotherapy.
2) Through computational modeling of miRNA and mRNA expression data, the researcher identified 5-miRNA signatures for ER-positive and ER-negative breast cancer.
3) In vitro experiments on breast cancer cell lines validated that the expressions of miRNAs in the signatures correlated with metastatic characteristics like migration, invasion and proliferation as predicted by the computational models.
This document summarizes recent research on the role of noncoding RNAs, such as microRNAs and long noncoding RNAs, in prostate cancer progression and castration-resistant prostate cancer. It discusses how some noncoding RNAs are regulated by the androgen receptor and promote tumor growth by influencing processes like apoptosis, cell cycle, and cell invasion. The expression levels of certain microRNAs have been associated with prostate cancer diagnosis, aggressiveness, and treatment resistance. Integrative analyses of androgen receptor binding sites and regulated transcripts have provided new insights into the complex molecular mechanisms driven by noncoding RNAs in prostate cancer.
This document summarizes a study that found keratinocytes from mice lacking the Tpl2 gene (Tpl2-/- mice) have increased expression of genes related to invasion and metastasis compared to keratinocytes from normal mice (Tpl2+/+ mice). Specifically, microarray analysis found over 2000 genes differentially expressed between the two types of keratinocytes. Tpl2-/- keratinocytes showed upregulation of several matrix metalloproteinase (MMP) genes involved in degradation of the extracellular matrix, including Mmp1b, Mmp2, Mmp9 and Mmp13. They also had downregulation of the MMP inhibitor Timp3. Further experiments confirmed higher MMP expression and activity in T
1. The study found that ADAM8, a protein highly expressed in triple-negative breast cancers, regulates the expression of miRNAs, including miR-720.
2. Experiments showed that ADAM8 induces miR-720 expression via activation of the β1-integrin/ERK signaling pathway.
3. Modulating miR-720 levels in triple-negative breast cancer cells revealed that miR-720 promotes migratory and invasive abilities, suggesting it plays a role in the aggressive phenotype driven by ADAM8.
This document summarizes a study investigating the role of microRNA-122 (miR-122) in regulating intrahepatic metastasis of hepatocellular carcinoma (HCC). The study found that miR-122 expression is significantly downregulated in HCC tumors with intrahepatic metastasis. Restoring miR-122 expression in metastatic HCC cell lines reduced in vitro migration, invasion, and tumor growth in vivo. Computational analysis identified multiple target genes of miR-122, including ADAM17, which was shown to be involved in metastasis. Silencing ADAM17 had similar effects as restoring miR-122, reducing in vitro and in vivo measures of metastasis. The study suggests that miR-122 acts as a tumor suppressor
This study investigated the association between the MMP-3 promoter polymorphism (-1171 5A->6A) and risk of oral submucous fibrosis (OSMF) and head and neck squamous cell carcinoma (HNSCC) in an Indian population. The authors genotyped 362 subjects, including 101 OSMF cases, 135 HNSCC cases, and 126 healthy controls. They found the 5A allele frequency was higher in OSMF (0.15) and HNSCC (0.13) compared to controls (0.07). Statistical analysis revealed a significant difference in 5A genotype frequency between OSMF and controls (p=0.01, OR=2.26) and between HNSCC
This document summarizes a study investigating the role of microRNA-302 in regulating retinal epithelial cell fate by targeting the TGF-β type II receptor. The study demonstrates that microRNA-302 promotes pluripotency in ARPE cells in vitro by regulating TGF-β signaling and epigenetic changes. It also shows that small molecules DZNEP and SB431542 can induce pluripotency by attenuating pathways involved in cell differentiation, supporting the potential for microRNAs and small molecules in regenerative medicine and therapeutics for diseases like diabetic retinopathy.
This study analyzed 264 gastric cancers for mutations in exons 9 and 20 of the PIK3CA gene. PIK3CA mutations were found in 42 cases (16%), all heterozygous missense mutations. The most common mutation was H1047R in exon 20 (62% of mutations) and the second most common was Q546K in exon 9 (9.5% of mutations). A meta-analysis of 27 publications found that the ratio of exon 20 to exon 9 mutations varied by cancer type, being highest in gastric cancer. The exon mutation selectivity is a signature of the cancer type.
miRNA Breast Cancer Prognosis -- Ingenuity SystemsNatalie Ng
1) The document describes research to develop microRNA prognostic signatures that can predict breast cancer metastasis and determine which patients would benefit from chemotherapy.
2) Through computational modeling of miRNA and mRNA expression data, the researcher identified 5-miRNA signatures for ER-positive and ER-negative breast cancer.
3) In vitro experiments on breast cancer cell lines validated that the expressions of miRNAs in the signatures correlated with metastatic characteristics like migration, invasion and proliferation as predicted by the computational models.
This document summarizes recent research on the role of noncoding RNAs, such as microRNAs and long noncoding RNAs, in prostate cancer progression and castration-resistant prostate cancer. It discusses how some noncoding RNAs are regulated by the androgen receptor and promote tumor growth by influencing processes like apoptosis, cell cycle, and cell invasion. The expression levels of certain microRNAs have been associated with prostate cancer diagnosis, aggressiveness, and treatment resistance. Integrative analyses of androgen receptor binding sites and regulated transcripts have provided new insights into the complex molecular mechanisms driven by noncoding RNAs in prostate cancer.
This document summarizes a study that found keratinocytes from mice lacking the Tpl2 gene (Tpl2-/- mice) have increased expression of genes related to invasion and metastasis compared to keratinocytes from normal mice (Tpl2+/+ mice). Specifically, microarray analysis found over 2000 genes differentially expressed between the two types of keratinocytes. Tpl2-/- keratinocytes showed upregulation of several matrix metalloproteinase (MMP) genes involved in degradation of the extracellular matrix, including Mmp1b, Mmp2, Mmp9 and Mmp13. They also had downregulation of the MMP inhibitor Timp3. Further experiments confirmed higher MMP expression and activity in T
1) GRK5 regulates prostate cancer cell migration and invasion in vitro and tumor growth and metastasis in vivo.
2) GRK5 phosphorylates the cytoskeletal protein moesin, regulating its subcellular distribution and localization to the cell periphery.
3) Phosphorylation of moesin at threonine 66 by GRK5 is important for cell spreading, and mutation of this site reduces cell spreading.
This document describes a study that conducted an RNA interference screening in breast cancer cells to identify epigenetic factors regulating the mesenchyme to epithelium transition (MET). Researchers designed a siRNA library targeting 729 chromatin modification genes and screened it in the mesenchymal breast cancer cell line MDA-MB-231. They identified 70 candidate genes involved in MET, including known genes like ZEB1, G9a, SMAD5 and SMARCD3, as well as DOT1L which has been implicated in MET. They also identified KAT5 as a novel gene linked to maintaining the mesenchymal phenotype for the first time. The screening approach involved measuring E-cadherin induction and cell
This document summarizes research on Cadm1, a gene that suppresses metastasis. Genetic analysis identified a locus on mouse chromosome 9 associated with metastasis. Cadm1 was validated as a metastasis-suppressing gene within this locus. Ectopic expression of Cadm1 reduced pulmonary metastasis in vivo, while knockdown increased metastasis. Cadm1 expression was associated with better survival in human breast cancer datasets. The mechanism of Cadm1's effect involves interaction with the cell-mediated immune system through proteins like CRTAM that activate CD8+ T cells and NK cells, reducing metastasis in an immune-dependent manner.
The document provides information about epithelial-mesenchymal transition (EMT) and its role in development, disease, and signaling pathways. It discusses:
1) The differences between epithelial and mesenchymal cell markers and properties. 2) How EMT converts epithelial cells into mesenchymal cells through disrupting cell adhesion and interactions with the extracellular matrix. 3) The transient and context-specific nature of EMT. 4) The role of EMT in embryogenesis, cancer progression and metastasis, and fibrosis. 5) Signaling pathways and factors that activate and suppress EMT such as TGF-β, Wnt, Notch, hypoxia, and inflammation. 6) How EMT generates cancer stem-like cells and
Inhibition of KPNA4 Attenuates Prostate Cancer MetastasisXin Li
This document summarizes a study examining the role of karyopherin α4 (KPNA4) in prostate cancer progression and metastasis. The study found that KPNA4 expression is positively correlated with prostate cancer stage and grade. Knockdown of KPNA4 reduced prostate cancer cell migration, invasion and distant metastasis in mouse models. Mechanistically, KPNA4 was found to be regulated by the tumor suppressive microRNA miR-708 and to modulate tumor necrosis factor (TNF)-α and -β expression through the nuclear factor kappa B (NF-κB) pathway to alter the tumor microenvironment and macrophage polarization.
Hepatocellular carcinoma (HCC) arises from mutations in genes that regulate cell growth. While over 40% of HCCs originate from cancer stem cells, the mechanisms of cancer stem cell formation are not fully understood. The transforming growth factor beta (TGF-β) signaling pathway plays an important role in suppressing tumor formation in the liver and intestinal stem cell niches. Loss of TGF-β signaling results in a phenotype similar to Beckwith-Wiedemann syndrome, which is associated with increased cancer risk. Understanding the TGF-β pathway and other key pathways involved in HCC formation could lead to new therapeutic strategies for preventing and treating this lethal cancer.
This document reports on a study that identified cysteine-rich protein 2 (CRP2) as a new component of breast cancer cell invadopodia that promotes invasion and metastasis. The study found that CRP2 expression is higher in mesenchymal/invasive breast cancer cells and its expression level correlates with increased risk of metastasis in basal-like breast cancer patients. CRP2 was shown to localize to the actin core of invadopodia, where it bundles actin filaments. Knockdown of CRP2 reduced breast cancer cell invasion, matrix degradation, and MMP-9 expression/secretion. Ectopic expression of CRP2 in less invasive cells increased invasion. Depletion of CR
- Certain miRNAs, such as miR-21 and miR-34a, show potential as biomarkers for the diagnosis and prognosis of pancreatic ductal adenocarcinoma (PDAC) as their expression levels correlate with cancer progression and patient survival.
- Inhibiting overexpressed miRNAs in PDAC, such as miR-21, miR-221 and miR-222, using antagomirs delivered via lipoplex nanoparticles reduced tumor cell proliferation, invasion and restored chemosensitivity in cell line studies.
- Epithelial-mesenchymal transition (EMT), which is regulated by transcription factors and miRNAs and promotes metastasis, plays an important role in PDAC development. Controlling pathways involved in EMT
This document summarizes key signaling pathways in muscle-invasive bladder carcinoma. It discusses molecular markers that indicate basal or luminal subtypes of bladder cancer, which differ in response to treatment. Basal cancers often overexpress EGFR and respond to chemotherapy, while luminal cancers involve alterations in genes like FGFR3, ERBB2/3 and are generally less aggressive. The document also reviews markers for cancer stem cells, receptor tyrosine kinase signaling pathways, cytoskeleton proteins, the PI3K-Akt-mTOR pathway, and VEGF/VEGFR pathways that are clinically significant for modeling and optimizing treatment of muscle-invasive bladder cancer.
Relationship between CCL5 and TGFβ1 in breast cancer patients at both systemi...Marion Hartmann
Chemokines are chemotactic cytokines that play an important role in inflammation through promotion of leukocyte motility. Studies have shown
that expression and activation of chemokine receptors promotes growth and
migration of primary tumour cells which leads to metastatic spread. Stromal-epithelial crosstalk in the tumour microenvironment is facilitated through
chemokines and their receptors. The chemokine (C-C motif) ligand 5 (CCL5) and its principle receptor CCR5 has a primary role in inflammation and has
been implicated in breast cancer progression. Previous studies linked elevated CCL5 serum levels with late stage breast cancer, similarly to what
has been described for transforming growth factor beta 1 (TGFβ1), a well established factor in tumourigenesis. TGFβ1 is thought to act as a tumour
suppressor in early stage disease and switch to being potentially tumour promoting in later stage breast cancer.
HDAC4 and HDAC7 Promote Breast and Ovarian Cancer Cell Migration by Regulatin...CrimsonpublishersCancer
Breast and ovarian cancer have been remained as a highly malignant tumor among women, posing a serious threat to women health worldwide. In this study, we were aimed to investigate the underlying mechanism of breast and ovarian cancer cell migration. Wound healing assay showed that MDA-MB-231and C13* have higher migration potential compare with MCF-7 and OV2078 cells, as well as regulated epithelial-mesenchymal transition (EMT) marker. We found that HDAC4 and HADC7 mRNA are up regulated in MDA-MB-231 and C13* cells. Moreover, target HDAC4 and HDAC7 by TSA or shRNA block MDA-MB-231and C13* migration. These results reveal a new link between HDACs and EMT in the regulation of breast and ovarian cancer migration.
This document reviews the role of microRNAs (miRNAs) in cancer. It discusses how miRNAs are involved in regulating gene expression and cellular processes. Aberrant miRNA expression has been found in many cancer types and can influence cancer-related signaling pathways. The document summarizes the mechanisms that can lead to abnormal miRNA expression levels in cancer, including genetic alterations, epigenetic changes, and defects in the miRNA biogenesis pathway. It also discusses how miRNA profiling can be used for cancer diagnosis and how circulating miRNA levels in body fluids are being investigated as potential non-invasive diagnostic biomarkers.
Cancer cells exhibit six hallmarks that allow tumor growth and metastasis. They are: self-sufficiency in growth signals, insensitivity to anti-growth signals, evading apoptosis, limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis. Cancer cells achieve these hallmarks through genetic and epigenetic alterations that disrupt normal cell signaling pathways.
The document summarizes Hanahan and Weinberg's hallmarks of cancer. It describes the six original hallmarks proposed in 2000 of self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, evading apoptosis, limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis. In 2011, they added two emerging hallmarks of deregulating cellular energetics and avoiding immune detection, as well as two enabling characteristics of genome instability and tumor-promoting inflammation.
This study examined the role of miR-138-5p in regulating human melanoma cell proliferation. The study found that miR-138-5p expression was significantly higher in melanoma tissues compared to controls. Overexpression of miR-138-5p promoted proliferation of Me45 melanoma cells, while inhibition of miR-138-5p suppressed proliferation. Bioinformatics analysis predicted that miR-138-5p targets the 3'-UTR of hTERT, and luciferase assays confirmed this. Knockdown of hTERT reversed the promotive effects of miR-138-5p on cell proliferation, indicating miR-138-5p regulates proliferation by directly targeting hTERT. Therefore, this study demonstrates that miR-138-5
This study found that colon cancer cells express the chemokine receptor CCR4, which mediates migration of the cells in response to its ligand CCL17 (TARC) through the RhoA/Rho kinase signaling pathway. Quantitative RT-PCR and flow cytometry showed that the colon cancer cell lines HT-29 and AZ-97 expressed CCR4 at both the mRNA and protein levels. Stimulation with CCL17 induced dose-dependent migration of the colon cancer cells, which was inhibited by blocking CCR4 with an antibody or antagonist. CCL17 also increased mRNA levels of RhoA proteins and RhoA activation in the cells. Inhibition of Rho kinase or isoprenylation blocked CCL17-induced cell migration
Hallmarks of cancer and radiopharmaceuticalsAlice Viana
In this presentation I review the article Hallmarks of cancer: next generation, from Hanahan and Weinberg, and make a parallel with potential and current targets of radiopharmaceuticals for diagnosis and treatment.
This study investigated the role of mitochondrial dynamics and the protein Drp1 in breast cancer cell apoptosis. Previous research showed that breast cancer HTB-22 cells have more fragmented mitochondria compared to non-cancerous controls, indicating a pro-fission phenotype. This study further characterized Drp1 function and found that more Drp1 translocates to the outer mitochondrial membrane in HTB-22 cells, which may explain their fragmented mitochondria. Future work will examine downstream apoptotic proteins like cytochrome c to determine how breast cancer cells resist apoptosis and continue proliferating.
- The document examines the role of plasminogen activator inhibitor 1 (PAI-1) in the recruitment of mast cells (MCs) to glioma tumors.
- It finds that neutralizing PAI-1 attenuates the infiltration of MCs into glioma tumors. It also finds that MCs express the PAI-1 receptor LRP1, and blocking LRP1 also attenuates MC migration.
- Activation of the potential PAI-1/LRP1 axis in MCs by purified PAI-1 promotes increased phosphorylation of STAT3 and subsequent MC exocytosis. This indicates the PAI-1/LRP1 axis influences MC recruitment in glioma tumors.
1. The study developed a novel 2.5D in vitro dot migration assay to better understand the invasive behaviors of proneural and mesenchymal glioblastoma tumor cells.
2. The assay incorporated both a surface (glass coverslip) and extracellular matrix components (Matrigel and FBS) to model the in vivo tumor microenvironment.
3. Preliminary results showed that the inflammatory cytokine TNF-alpha promoted greater cellular adhesion and dissemination of proneural PBT003 tumor cells in the assay, supporting one of the study's hypotheses. Further testing of additional cell lines was needed to fully evaluate the hypotheses.
This document describes a project to build a GPS and GSM-enabled robot that can be controlled wirelessly. The robot uses a microcontroller, LCD display, GPS module, GSM module, and relay to determine its location using GPS and receive wireless control commands via GSM to move forward, backward, left, right, or stop. It displays the robot's movement on the LCD. The complete circuit diagram, working, program code, and components are explained.
Este documento resume la ficha técnica y análisis de un cortometraje de animación titulado "Tadeo Jones y la mano de Nefertiti". El corto sigue las aventuras de Jeff el perro y Belzoni el loro mientras cuidan una mano egipcia en un museo. Cuando la mano cobra vida mágicamente, los personajes deben devolverla a su urna y embellecerla. El documento analiza los elementos técnicos como planos, movimientos de cámara y género, concluyendo que aunque
1) GRK5 regulates prostate cancer cell migration and invasion in vitro and tumor growth and metastasis in vivo.
2) GRK5 phosphorylates the cytoskeletal protein moesin, regulating its subcellular distribution and localization to the cell periphery.
3) Phosphorylation of moesin at threonine 66 by GRK5 is important for cell spreading, and mutation of this site reduces cell spreading.
This document describes a study that conducted an RNA interference screening in breast cancer cells to identify epigenetic factors regulating the mesenchyme to epithelium transition (MET). Researchers designed a siRNA library targeting 729 chromatin modification genes and screened it in the mesenchymal breast cancer cell line MDA-MB-231. They identified 70 candidate genes involved in MET, including known genes like ZEB1, G9a, SMAD5 and SMARCD3, as well as DOT1L which has been implicated in MET. They also identified KAT5 as a novel gene linked to maintaining the mesenchymal phenotype for the first time. The screening approach involved measuring E-cadherin induction and cell
This document summarizes research on Cadm1, a gene that suppresses metastasis. Genetic analysis identified a locus on mouse chromosome 9 associated with metastasis. Cadm1 was validated as a metastasis-suppressing gene within this locus. Ectopic expression of Cadm1 reduced pulmonary metastasis in vivo, while knockdown increased metastasis. Cadm1 expression was associated with better survival in human breast cancer datasets. The mechanism of Cadm1's effect involves interaction with the cell-mediated immune system through proteins like CRTAM that activate CD8+ T cells and NK cells, reducing metastasis in an immune-dependent manner.
The document provides information about epithelial-mesenchymal transition (EMT) and its role in development, disease, and signaling pathways. It discusses:
1) The differences between epithelial and mesenchymal cell markers and properties. 2) How EMT converts epithelial cells into mesenchymal cells through disrupting cell adhesion and interactions with the extracellular matrix. 3) The transient and context-specific nature of EMT. 4) The role of EMT in embryogenesis, cancer progression and metastasis, and fibrosis. 5) Signaling pathways and factors that activate and suppress EMT such as TGF-β, Wnt, Notch, hypoxia, and inflammation. 6) How EMT generates cancer stem-like cells and
Inhibition of KPNA4 Attenuates Prostate Cancer MetastasisXin Li
This document summarizes a study examining the role of karyopherin α4 (KPNA4) in prostate cancer progression and metastasis. The study found that KPNA4 expression is positively correlated with prostate cancer stage and grade. Knockdown of KPNA4 reduced prostate cancer cell migration, invasion and distant metastasis in mouse models. Mechanistically, KPNA4 was found to be regulated by the tumor suppressive microRNA miR-708 and to modulate tumor necrosis factor (TNF)-α and -β expression through the nuclear factor kappa B (NF-κB) pathway to alter the tumor microenvironment and macrophage polarization.
Hepatocellular carcinoma (HCC) arises from mutations in genes that regulate cell growth. While over 40% of HCCs originate from cancer stem cells, the mechanisms of cancer stem cell formation are not fully understood. The transforming growth factor beta (TGF-β) signaling pathway plays an important role in suppressing tumor formation in the liver and intestinal stem cell niches. Loss of TGF-β signaling results in a phenotype similar to Beckwith-Wiedemann syndrome, which is associated with increased cancer risk. Understanding the TGF-β pathway and other key pathways involved in HCC formation could lead to new therapeutic strategies for preventing and treating this lethal cancer.
This document reports on a study that identified cysteine-rich protein 2 (CRP2) as a new component of breast cancer cell invadopodia that promotes invasion and metastasis. The study found that CRP2 expression is higher in mesenchymal/invasive breast cancer cells and its expression level correlates with increased risk of metastasis in basal-like breast cancer patients. CRP2 was shown to localize to the actin core of invadopodia, where it bundles actin filaments. Knockdown of CRP2 reduced breast cancer cell invasion, matrix degradation, and MMP-9 expression/secretion. Ectopic expression of CRP2 in less invasive cells increased invasion. Depletion of CR
- Certain miRNAs, such as miR-21 and miR-34a, show potential as biomarkers for the diagnosis and prognosis of pancreatic ductal adenocarcinoma (PDAC) as their expression levels correlate with cancer progression and patient survival.
- Inhibiting overexpressed miRNAs in PDAC, such as miR-21, miR-221 and miR-222, using antagomirs delivered via lipoplex nanoparticles reduced tumor cell proliferation, invasion and restored chemosensitivity in cell line studies.
- Epithelial-mesenchymal transition (EMT), which is regulated by transcription factors and miRNAs and promotes metastasis, plays an important role in PDAC development. Controlling pathways involved in EMT
This document summarizes key signaling pathways in muscle-invasive bladder carcinoma. It discusses molecular markers that indicate basal or luminal subtypes of bladder cancer, which differ in response to treatment. Basal cancers often overexpress EGFR and respond to chemotherapy, while luminal cancers involve alterations in genes like FGFR3, ERBB2/3 and are generally less aggressive. The document also reviews markers for cancer stem cells, receptor tyrosine kinase signaling pathways, cytoskeleton proteins, the PI3K-Akt-mTOR pathway, and VEGF/VEGFR pathways that are clinically significant for modeling and optimizing treatment of muscle-invasive bladder cancer.
Relationship between CCL5 and TGFβ1 in breast cancer patients at both systemi...Marion Hartmann
Chemokines are chemotactic cytokines that play an important role in inflammation through promotion of leukocyte motility. Studies have shown
that expression and activation of chemokine receptors promotes growth and
migration of primary tumour cells which leads to metastatic spread. Stromal-epithelial crosstalk in the tumour microenvironment is facilitated through
chemokines and their receptors. The chemokine (C-C motif) ligand 5 (CCL5) and its principle receptor CCR5 has a primary role in inflammation and has
been implicated in breast cancer progression. Previous studies linked elevated CCL5 serum levels with late stage breast cancer, similarly to what
has been described for transforming growth factor beta 1 (TGFβ1), a well established factor in tumourigenesis. TGFβ1 is thought to act as a tumour
suppressor in early stage disease and switch to being potentially tumour promoting in later stage breast cancer.
HDAC4 and HDAC7 Promote Breast and Ovarian Cancer Cell Migration by Regulatin...CrimsonpublishersCancer
Breast and ovarian cancer have been remained as a highly malignant tumor among women, posing a serious threat to women health worldwide. In this study, we were aimed to investigate the underlying mechanism of breast and ovarian cancer cell migration. Wound healing assay showed that MDA-MB-231and C13* have higher migration potential compare with MCF-7 and OV2078 cells, as well as regulated epithelial-mesenchymal transition (EMT) marker. We found that HDAC4 and HADC7 mRNA are up regulated in MDA-MB-231 and C13* cells. Moreover, target HDAC4 and HDAC7 by TSA or shRNA block MDA-MB-231and C13* migration. These results reveal a new link between HDACs and EMT in the regulation of breast and ovarian cancer migration.
This document reviews the role of microRNAs (miRNAs) in cancer. It discusses how miRNAs are involved in regulating gene expression and cellular processes. Aberrant miRNA expression has been found in many cancer types and can influence cancer-related signaling pathways. The document summarizes the mechanisms that can lead to abnormal miRNA expression levels in cancer, including genetic alterations, epigenetic changes, and defects in the miRNA biogenesis pathway. It also discusses how miRNA profiling can be used for cancer diagnosis and how circulating miRNA levels in body fluids are being investigated as potential non-invasive diagnostic biomarkers.
Cancer cells exhibit six hallmarks that allow tumor growth and metastasis. They are: self-sufficiency in growth signals, insensitivity to anti-growth signals, evading apoptosis, limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis. Cancer cells achieve these hallmarks through genetic and epigenetic alterations that disrupt normal cell signaling pathways.
The document summarizes Hanahan and Weinberg's hallmarks of cancer. It describes the six original hallmarks proposed in 2000 of self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, evading apoptosis, limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis. In 2011, they added two emerging hallmarks of deregulating cellular energetics and avoiding immune detection, as well as two enabling characteristics of genome instability and tumor-promoting inflammation.
This study examined the role of miR-138-5p in regulating human melanoma cell proliferation. The study found that miR-138-5p expression was significantly higher in melanoma tissues compared to controls. Overexpression of miR-138-5p promoted proliferation of Me45 melanoma cells, while inhibition of miR-138-5p suppressed proliferation. Bioinformatics analysis predicted that miR-138-5p targets the 3'-UTR of hTERT, and luciferase assays confirmed this. Knockdown of hTERT reversed the promotive effects of miR-138-5p on cell proliferation, indicating miR-138-5p regulates proliferation by directly targeting hTERT. Therefore, this study demonstrates that miR-138-5
This study found that colon cancer cells express the chemokine receptor CCR4, which mediates migration of the cells in response to its ligand CCL17 (TARC) through the RhoA/Rho kinase signaling pathway. Quantitative RT-PCR and flow cytometry showed that the colon cancer cell lines HT-29 and AZ-97 expressed CCR4 at both the mRNA and protein levels. Stimulation with CCL17 induced dose-dependent migration of the colon cancer cells, which was inhibited by blocking CCR4 with an antibody or antagonist. CCL17 also increased mRNA levels of RhoA proteins and RhoA activation in the cells. Inhibition of Rho kinase or isoprenylation blocked CCL17-induced cell migration
Hallmarks of cancer and radiopharmaceuticalsAlice Viana
In this presentation I review the article Hallmarks of cancer: next generation, from Hanahan and Weinberg, and make a parallel with potential and current targets of radiopharmaceuticals for diagnosis and treatment.
This study investigated the role of mitochondrial dynamics and the protein Drp1 in breast cancer cell apoptosis. Previous research showed that breast cancer HTB-22 cells have more fragmented mitochondria compared to non-cancerous controls, indicating a pro-fission phenotype. This study further characterized Drp1 function and found that more Drp1 translocates to the outer mitochondrial membrane in HTB-22 cells, which may explain their fragmented mitochondria. Future work will examine downstream apoptotic proteins like cytochrome c to determine how breast cancer cells resist apoptosis and continue proliferating.
- The document examines the role of plasminogen activator inhibitor 1 (PAI-1) in the recruitment of mast cells (MCs) to glioma tumors.
- It finds that neutralizing PAI-1 attenuates the infiltration of MCs into glioma tumors. It also finds that MCs express the PAI-1 receptor LRP1, and blocking LRP1 also attenuates MC migration.
- Activation of the potential PAI-1/LRP1 axis in MCs by purified PAI-1 promotes increased phosphorylation of STAT3 and subsequent MC exocytosis. This indicates the PAI-1/LRP1 axis influences MC recruitment in glioma tumors.
1. The study developed a novel 2.5D in vitro dot migration assay to better understand the invasive behaviors of proneural and mesenchymal glioblastoma tumor cells.
2. The assay incorporated both a surface (glass coverslip) and extracellular matrix components (Matrigel and FBS) to model the in vivo tumor microenvironment.
3. Preliminary results showed that the inflammatory cytokine TNF-alpha promoted greater cellular adhesion and dissemination of proneural PBT003 tumor cells in the assay, supporting one of the study's hypotheses. Further testing of additional cell lines was needed to fully evaluate the hypotheses.
This document describes a project to build a GPS and GSM-enabled robot that can be controlled wirelessly. The robot uses a microcontroller, LCD display, GPS module, GSM module, and relay to determine its location using GPS and receive wireless control commands via GSM to move forward, backward, left, right, or stop. It displays the robot's movement on the LCD. The complete circuit diagram, working, program code, and components are explained.
Este documento resume la ficha técnica y análisis de un cortometraje de animación titulado "Tadeo Jones y la mano de Nefertiti". El corto sigue las aventuras de Jeff el perro y Belzoni el loro mientras cuidan una mano egipcia en un museo. Cuando la mano cobra vida mágicamente, los personajes deben devolverla a su urna y embellecerla. El documento analiza los elementos técnicos como planos, movimientos de cámara y género, concluyendo que aunque
This document provides an overview of factors to consider when selling a home. It discusses 5 reasons why now is a good time to sell, including strong buyer demand, less competition from other sellers, a quicker home selling process, benefits of moving up to a more expensive home now before prices increase further, and being able to move on with your life goals. It emphasizes the importance of using a real estate agent when selling, as most buyers rely on an agent despite using the internet in their home search. It also stresses the importance of properly pricing your home initially to avoid future price reductions and get the best price.
Adaptive Control of a Robotic Arm Using Neural Networks Based ApproachWaqas Tariq
A new neural networks and time series prediction based method has been discussed to control the complex nonlinear multi variable robotic arm motion system in 3d environment without engaging the complicated and voluminous dynamic equations of robotic arms in controller design stage, the proposed method gives such compatibility to the manipulator that it could have significant changes in its dynamic properties, like getting mechanical loads, without need to change designs of the controller.
1. The document discusses differential kinematics and how it can be used to examine the pose velocities of robot frames. It also covers Jacobians and how they map between joint and Cartesian space velocities.
2. Specific topics covered include differential transformations, screw velocity matrices, relating velocities in different frames, determining Jacobians for serial and parallel robots, and examining robot singularities.
3. Singularities occur when the mechanism loses mobility in certain directions and joint rates will increase near these configurations. Workarounds include tooling design, changing to joint space control near singularities, and carefully planning paths.
Automation technologies in road construction can improve inspection and tracking of projects. Tablets and scanning software can track material quantities, locations, and specifications delivered to sites. High-accuracy GPS systems, which have become more affordable, can check contractor work for grade and location. Robotic systems guided by GPS are also increasingly used for stringless paving and subgrade preparation, allowing for accurate construction layout. Proper use of these technologies can help complete higher quality projects more easily and efficiently.
A systemic review on in vivo & in vitro models of angiogenesis & preliminary ...Abhijeet Mihir
This document provides a summary of 3 key points about angiogenesis:
1. Angiogenesis is the growth of new blood vessels from pre-existing vessels. It is a normal process in growth and wound healing but also plays a role in diseases where there is either too much or too little blood vessel growth.
2. There are multiple types of angiogenesis including sprouting, intussusception, and recruitment of endothelial progenitor cells. Sprouting is the main type where new vessels branch off existing ones.
3. Angiogenesis is controlled by a balance of pro-angiogenic and anti-angiogenic factors. Diseases occur when this balance is disrupted, leading to either excessive or insufficient new blood vessel formation
In vitro and in vivo models of angiogenesisVijay Avin BR
This document discusses in vitro and in vivo models for studying angiogenesis. It describes several in vitro models including cord formation assays, tube formation assays, cell migration assays, cell proliferation assays, and gelatin zymography that are used to study the molecular mechanisms and identify regulators of angiogenesis. Important considerations for developing angiogenesis studies include choosing an appropriate endothelial cell source and extracellular matrix. Several in vivo models are also described such as the rabbit corneal assay, sponge implantation models, matrigel plug assays, and the hind limb ischemia model. Both in vitro and in vivo techniques are important for advancing the understanding and treatment of diseases associated with angiogenesis like cancer.
~~ Avatar's i.e. incarnation for the god narayan & the god vishnu ~~Deepak Somaji Sawant
This document summarizes information from two Hindu religious texts about the incarnations of the gods Vishnu and Narayan. It describes 20 incarnations of Narayan including Kumara, Varaha, and Krishna. It then details 10 avatars of Vishnu including Matsya, Kurma, Varaha, Nrusinha, Vamana, Parashurama, Rama, Krishna, and the future Kalki avatar. It explains that Vishnu rests in the ocean on Shesha and periodically awakens to create new worlds during the end of epochs, taking new incarnations suited to each new era.
The document discusses empirical and molecular formulas. An empirical formula shows the simplest whole number ratio of atoms in a compound, while a molecular formula shows the exact number of each atom. To calculate molecular formula from empirical formula: 1) make a table with elements, percentages, atomic masses, moles, and simplest ratios; 2) the empirical formula mass is the sum of the atoms' masses; 3) divide the molar mass by the empirical formula mass to get the common factor for the molecular formula. Two examples are given to calculate empirical and molecular formulas from percentage compositions and molar masses.
1. Organic reaction mechanisms involve the reaction of a substrate with a reagent, forming intermediates and ultimately products.
2. Bond cleavage can occur through either a heterolytic or homolytic process. Heterolytic cleavage leads to the formation of ions while homolytic cleavage leads to free radicals.
3. Electrophiles are electron seeking species that attack nucleophilic centers, while nucleophiles are electron pairing species that attack electrophilic centers. Common electrophiles include carbocations and carbonyl groups, while common nucleophiles include carbanions.
MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and affect multiple cellular processes. Dysregulation of miRNAs is common in cancer and can impact cancer hallmarks like sustained proliferation, evading growth suppression, resisting cell death, and activating invasion and metastasis. Certain miRNAs are considered oncogenes when their expression is increased in tumors, while others act as tumor suppressors when their expression is decreased. Altered miRNA expression and biogenesis machinery defects contribute to cancer development and progression. miRNAs also show potential as cancer biomarkers and therapeutic targets.
This document reviews the role of microRNAs (miRNAs) in the occurrence and development of esophageal squamous cell carcinoma (ESCC). It summarizes that various miRNAs have been found to be dysregulated in ESCC and can function either as tumor suppressors or oncogenes by targeting different genes involved in processes like cell proliferation, apoptosis and invasion. Specifically, it provides tables listing miRNAs that have been identified as tumor suppressors and oncogenes in ESCC, along with their biological effects and target genes. The document aims to enhance understanding of the molecular mechanisms by which miRNAs contribute to the progression of ESCC.
1) Prodigiosin, a bacterial metabolite, induces apoptosis in human breast cancer cells. Gene expression profiling found that prodigiosin strongly increased expression of the NAG-1 gene.
2) Experiments showed that prodigiosin triggers accumulation of the tumor suppressor protein p53, but induction of NAG-1 was independent of p53.
3) Prodigiosin causes inhibition of AKT and activation of glycogen synthase kinase-3B (GSK-3B). Induction of NAG-1 and apoptosis correlated with GSK-3B activation. Inhibiting GSK-3B reduced apoptosis, suggesting GSK-3B plays a key role in the proap
Canine oncoprotein targets for Melanoma, Breast Cancer, OsteosarcomaSnehal Salunkhe
We can acquire the basic knowledge about canine oncoprotein targets specifically for Melanoma, Osteosarcoma and Breast cancer. I haven't mentioned all the proteins and their targets involved, but just a general overview of these targets with the drugs involved in their treatment/clinical trials.
This study explored the role of miR-630 in enhancing the chemotherapeutic sensitivity of BRCA1 mutant triple-negative breast cancer (TNBC) cell lines. The researchers found that combining carboplatin and gemcitabine chemotherapy with the PARP inhibitor olaparib upregulated miR-630 expression in BRCA1 mutant MDA-MB-436 and HCC1937 TNBC cell lines. Overexpression of miR-630 suppressed cell proliferation, migration, and invasion, whereas inhibition of miR-630 increased these effects. Therefore, miR-630 plays an important tumor suppressor role in increasing the chemotherapeutic sensitivity of PARP inhibitors for BRCA1 mutant TNBC, which may be one mechanism of how PAR
Molecular Pathogenesis and mechanisms of carcinogenesis involve several key hallmarks and changes in cell physiology that drive cancer development and progression. The hallmarks include self-sufficiency in growth signals, evasion of growth suppression, resistance to cell death, replication immortality, induction of angiogenesis, activation of invasion and metastasis, immune evasion, microRNA involvement, and epigenetic alterations. Cancer results from dysregulation of oncogenes and tumor suppressor genes that control the normal cell cycle and proliferation.
This document discusses molecular parameters that have prognostic or predictive value in colorectal cancer. It summarizes that microsatellite instability (MSI) confers a favorable prognosis while chromosome instability (CIN) indicates an unfavorable prognosis. Certain gene mutations like KRAS and BRAF also have prognostic or predictive significance. Molecular testing for markers like methylated DNA in stool samples shows potential as a noninvasive screening method for early detection of colorectal cancer.
This document discusses new strategies for combating cancer through molecular biology approaches. It describes prevention strategies that focus on pre-invasive lesions by inhibiting carcinogen initiation events, cell proliferation associated with promotion, or the development of the invasive phenotype in precancerous lesions. Targets for prevention strategies include biochemical species produced by carcinogens and aberrantly expressed proteins from genetic/environmental risk factors. Gene expression profiling using cDNA microarrays can help understand carcinogenesis at the molecular level and identify new therapeutic targets. The document also discusses inhibiting metastasis through strategies like modifying cell adhesion with MMP inhibitors or anticoagulants, and inhibiting angiogenesis. Gene therapy approaches for cancer treatment aim to correct genetic mutations or deliver therapeutic genes to stimulate anti-tumor immune
This document discusses newer tumor markers that can be used for cancer diagnosis, prognosis, and monitoring treatment. It describes various types of biochemical entities that serve as tumor markers, including nucleic acids, proteins, sugars, lipids, and whole tumor cells. Specific examples of tumor markers are discussed, such as enzymes, hormones, oncofetal antigens, tumor-associated proteins, carbohydrate antigens, and genetic markers. The ideal properties of tumor markers and their clinical applications are also summarized.
1. Cancer develops through genetic changes in cells, including mutations in oncogenes and tumor suppressor genes.
2. Tumor suppressor genes normally inhibit cell proliferation and promote apoptosis but their inactivation allows for uncontrolled cell growth.
3. Examples of important tumor suppressor genes discussed include RB, p53, PTEN, BRCA1, and BRCA2. Their protein products regulate processes like cell cycle arrest, DNA repair, and apoptosis.
This document discusses gene therapy as a promising treatment for breast cancer. It begins by providing background on breast cancer prevalence and current treatment options. It then describes how gene therapy could target mutated genes, cancer cell markers, block metastasis, and induce apoptosis. The document focuses on gene therapy approaches for breast cancer, including using antisense technology to inhibit pathogenic genes, RNA interference to downregulate genes like c-myc, and suicide genes to make cancer cells more sensitive to chemotherapy.
ONCOGENE AND PROTOONCOGENE
P53 GENE AND ITS APPLICATION IN CANCER ETIOLOGY
TUMOUR SUPPRESSOR GENE AND BCA AND BAC GENE AND ITS APPLICATION ON THE APOPTOSIS AND DEATH RECEPTORS
Radiotherapy promotes the polarization of tumor-associated macrophages (TAMs) in mice with Lewis lung cancer into anti-tumor M1 macrophages. This is accompanied by increased expression of the long non-coding RNA lincRNA-p21 in the TAMs. TAMs exposed to radiation therapy suppress the viability and invasion of Lewis lung cancer cells in culture. Overexpression of lincRNA-p21 in TAMs enhances their anti-tumor effects, while decreasing lincRNA-p21 reduces the effects of radiation therapy, suggesting lincRNA-p21 plays a key role in the anti-tumor actions of radiotherapy in lung cancer.
This document discusses tumor suppressor genes. It begins by explaining that cancer is caused by genetic mutations, and describes the characteristic properties of cancer cells that result from these genetic changes. It then discusses two classes of genes affected in cancer - oncogenes and tumor suppressor genes. Oncogenes contribute to tumor development, while tumor suppressors support tumor development when their function is lost. The rest of the document provides details on specific tumor suppressor genes like RB, p53, PTEN, NF1, and BRCA1/2; their functions in inhibiting cell growth and proliferation; and the genetic and epigenetic mechanisms by which their inactivation can lead to cancer development.
This document provides an overview of oncogenes and tumor suppressor genes and their role in cancer initiation and progression. It discusses how mutations in proto-oncogenes can activate them into oncogenes, causing increased or altered protein production and stimulating cell proliferation. Tumor suppressor genes normally inhibit cell growth but mutations can repress them, deregulating the cell cycle. The interactions between oncogene activation and tumor suppressor gene inactivation are required for full malignant transformation. Understanding these genetic factors involved in carcinogenesis can provide insights into cancer prevention, diagnosis, and treatment.
A normal cell can be transformed into a cancerous cell. Discuss the therapeutic strategies that are employed to target the cellular transformation process for cancer prevention and treatment.
cancer pharmaco therapeutics - 3.3 1.pptxmathihadassa
Cancer develops through a multistage process of genetic mutations that alter the normal control of cellular growth and proliferation. The initial step is initiation by carcinogens, which cause DNA damage and mutations in proto-oncogenes and tumor suppressor genes. This gives cells a selective growth advantage. Promotion makes the environment favor growth of these mutated cells. Finally, progression leads to increased proliferation and metastasis. Oncogenes stimulate growth while tumor suppressors inhibit it. Loss of control over these genes, through acquired or inherited mutations, drives carcinogenesis.
As an uncommon malignant tumor, hypopharyngeal cancer accounts for 3–5% of head and neck tumors [1]. Most pathological types of hypopharyngeal cancer are squamous cell carcinoma. Due to the occult anatomical location of hypopharyngeal cancer and poor surgical effect, local recurrence or distant metastasis often occurs in patients with hypopharyngeal cancer following surgery.
Mmp13 and serpinb2 as novel biomarkers for hypopharyngeal cancer
MasterThesis
1. 1
UNIVERSITA’ DEGLI STUDI DI TORINO
STRUTTURA DIDATTICA SPECIALE DI BIOTECNOLOGIE
TESI DI LAUREA SPECIALISTICA
MORGANA: A KEY PLAYER IN BREAST CANCER
METASTASIZATION
CANDIDATA RELATORE
Elena Busso Prof. Mara Brancaccio
ANNO ACCADEMICO 2015/2015
2. 2
INDEX
INTRODUCTION
MATERIALS AND METHODS
Cell culture
Antibodies, Reagents and Plasmids
Immunofluorescence
Protein extraction and Western Blot
In vivo tumor and metastasis assay
Cell pellet preparation and Immunohistochemical analysis
Migration and Invasion Assay
Gelatin Zymography
RNA isolation and qRT-PCR
Transfection and Luciferase Assay
Statistical Significance
RESULTS
Morgana knockdown cells show impaired migration and invasion in vitro
Morgana knockdown cells show impaired metastasis formation in vivo
Morgana downregulation causes a decrease in MMP-9 activity and expression
Morgana effect on MMP-9 expression is not dependent on ROCK/PTEN/AKT pathway
Morgana regulates MMP-9 expression through the NF-kappaB transcription factor
Morgana overexpressing cells show increased expression of NF-kappaB target genes
Morgana can modulate the NF-kappaB pathway
DISCUSSION AND FUTURE PERSPECTIVES
ACKNOWLEDGMENTS
REFERENCES
FIGURES AND TABLES
3. 3
ABSTRACT
Morgana is a ubiquitously expressed protein, which has been shown to act as an hsp90
co-chaperone and to inhibit ROCK activity. In a small subset of human breast cancer
samples, morgana has been found expressed at higher levels compared to normal
tissues and, moreover, morgana overexpression correlates with tumor grade, mitotic
index and lymph node involvement, regardless of the breast cancer subtype. It has
been recently demonstrated that morgana overexpression in breast cancer cells leads
to chemoresistance, through the ROCK/PTEN/AKT axis. Here we show that morgana is
required for invasion and migration of aggressive breast cancer cells in vitro and for
their ability to form metastasis in vivo. From a mechanistic point of view, we
demonstrated that high morgana levels cause an increase in the transcriptional activity
of NF-kappaB, which in turn drives the transcription of several target genes, including
metalloproteinases and inflammation genes, which have been shown to promote
metastasis formation.
4. 4
INTRODUCTION
Morgana/chp-1 has been characterized as a ubiquitously expressed CHP (CHORD
containing protein), composed of two CHORD domains and a CS (after CHORD-
containing proteins and Sgt1) domain [1]. CHORDs (cysteine and histidine rich
domains) are 60-amino acids Zn2+
binding motifs, characterized by unique cysteine and
histidine sequence patterns [1]. These domains were first identified in the plant
protein Rar1, which is composed of two tandemly repeated CHORD domains and an
additional 20 aminoacid sequence motif, absent in non-plant species [1]. Not
vertebrates, with the exception of yeast, express CHPs with an additional C-terminal CS
domain. The CS domain is also present in Sgt1, a multifunctional protein present both
in plants and animals. While in plants the CHORD and CS domains are present on
distinct proteins (Rar1 and Sgt1) but their physical interaction is required for their
biological function, not vertebrates and vertebrates express CHPs containing both
CHORD domains and a CS domain. Moreover, in vertebrates there are two different
CHP genes, codifying for the ubiquitously expressed morgana and the muscle-specific
melusin, thus suggesting that during evolution the ancestral gene underwent
duplication [2].
It has been demonstrated that morgana/chp-1 knockout mice are embryonic lethal
and that morgana null Drosophila die as instar larvae due to strong proliferation
defects. Moreover, larvae neuroblasts show a strong mitotic phenotype, characterized
by high frequency of diploid cells with supernumerary centrosomes [3]. Interestingly,
the human morgana ortholog can fully rescue the fly centrosome phenotype [3],
5. 5
suggesting a conserved role for morgana between mammals and Drosophila. It has
been shown that morgana can interact with Hsp90 [3], acting as a co-chaperone [4],
and with ROCKI and ROCKII [3], inhibiting their activity. Moreover, mouse embryonic
fibroblasts (MEFs) derived from morgana +/- mice have an higher frequency of
polyploidy cells, supernumerary centrosomes and multipolar spindles [3]. These
characteristics are all important features of cancer progression [5] and, accordingly,
morgana +/- mice are more susceptible to chemical mutagenesis compared to wild-
type cells and display oncogenic features in culture [3]. Importantly, morgana is
strongly downregulated in 67.3% of human breast and 57.7% of human lung cancer
samples compared with control tissues [3], thus suggesting a causative role for
morgana downregulation in cancer onset in human. Furthermore, we recently
demonstrated that morgana haploinsufficient mice develop a myeloproliferative
neoplasm resembling human atypical chronic myeloid leukemia [6]. However, our
tissue array analysis showed that, unexpectedly, morgana is also overexpressed in a
small fraction of human breast (5.4%) and lung cancers (10.3%) [3]. This intriguing
result was further investigated, and recently it has been demonstrated that morgana
overexpression induces transformation in NIH-3T3 cells and strongly protects them
from apoptosis induced by various apoptotic stimuli and from anoikis [7]. From a
mechanistic point of view, high morgana levels inhibit ROCKI, thus destabilizing PTEN
and triggering the PI3K-AKT survival pathway. Accordingly, when morgana is
downregulated in MDA-MB-231 and T47D, PTEN expression increases and leads to cell
sensitization to chemotherapy [7]. In normal breast epithelium-derived cell lines (such
as MCF-10A) and in not aggressive breast cancer cell lines (such as MCF-7), morgana is
expressed at low levels, while breast cancer-derived cell lines (MDA-MB-231, T47D)
6. 6
express morgana at higher levels. Thus, the more aggressive the phenotype, the higher
is morgana expression [7].
Intriguingly, it has been demonstrated that morgana is associated with an
aggressive phenotype in human breast cancers: within different subtypes, morgana
overexpression correlates with high tumor grade, mitosis number and percentage of
Ki67 positive cells [7]. Moreover, morgana is overexpressed with higher incidence
(36%) in triple negative breast cancers, indicating a putative role for morgana in
sustaining a more aggressive phenotype. The term triple negative breast cancer is used
to identify approximately the 15% of breast cancers that lacks the expression of
estrogen receptor (ER) and progesterone receptor (PR) and which do not have the
amplification of the human epidermal growth factor receptor 2 (HER2) [8]. These
cancers are characterized by increased aggressiveness, higher rate of relapse and
worst survival. The absence of a high frequency alteration and the lack of specific
biomarkers is the major obstacle in the development of a successful therapeutic
strategy [8]. Furthermore, morgana correlates with lymph node involvement (pN) [7],
which is an index indicating how much the tumor has spread outside the site of origin,
thus its attitude to give rise to metastasis.
Metastasis are the end product of a multistep cell-biological process called the
“invasion-metastasis cascade”, which involves migration of cancer cells from their site
of origin, dissemination into distant organs and subsequent adaptation to the new
extracellular environment [9]. During the metastatic progression, tumor cells need to
overcome a series of steps: exit their primary sites of growth (local invasion and
intravasation), translocate systemically (survive in the circulation, arrest at distant
7. 7
organ sites, extravasate), and adapt to survive in the foreign microenvironment of
distant tissues (micrometastasis formation and metastatic colonization) [10]. Each step
of this process not only requires cancer cells to acquire several properties by genetic or
epigenetic alteration, but also depends upon the cooperation between cancer and
stromal cells. Alteration of cellular adhesion and cell motility, resistance to
extracellular death signals, disruption of basement membrane and extracellular matrix
(ECM) are among the most common alterations needed for metastasization [9].
In particular, ECM proteases are intrinsically associated with breast tissue
remodeling and cancer, since they mediate enzymatic degradation of the extracellular
matrix and of the basement membrane [11]. The activity of matrix proteases is
normally under tight control through specific localization, autoinhibition and secreted
tissue inhibitors [9]. Cancerous cells use diverse mechanisms to disrupt this tight
regulation and unleash proteolytic activity on the basement membrane and interstitial
extracellular matrices. In addition to facilitating tumor environment, extracellular
proteases can generate a diverse array of active cleaved peptides that can modulate
migration, cancer-cell proliferation, survival, and tumor angiogenesis [12]. Matrix
metalloproteinases are the most prominent proteases during breast cancer
progression: studies have reported that within the matrix metalloproteinase (MMP)
family, gelatinases A (72 kDa gelatinase, type IV collagenase and MMP-2) and B (92
kDa gelatinase, type IV collagenase and MMP-9) play a critical role in ECM degradation
and cell migration, leading to tumor cell invasion in breast cancer [13]. Elevated MMP-
9 levels have been functionally linked to elevated metastasis formation in a number of
tumor types, such as brain, prostate, bladder and breast tumors [12]. Consequently,
inhibiting the expression of MMP-9 and/or its upstream regulatory pathways may
8. 8
prove to be effective in treating malignant tumors, including breast cancer.
Unfortunately, this first effort has been unsuccessful due to the several joint disorders
caused by these inhibitors [14], thus better understanding the activity of these
proteins is crucial in order to design a new generation of more effective protease
inhibitors. MMPs are not coordinately regulated at the transcriptional level: their
transcription is independently regulated, and each cell displays a proteolytic
phenotype in response to a particular stimulus. Several factors have been
demonstrated to be involved in the overexpression of MMPs in tumors, among them
interleukin (IL-1) and tumor necrosis factor (TNFα). The signal transduction pathway
that mediates the expression of metalloproteinases are diverse and the most
important is the mitogen activated kinase (MAPK) pathway, which stimulates or inhibit
MMPs expression depending on the cell type. Most of these pathways converge at the
transcription factors AP-1 and NF-kappaB, whose binding sites are present in the
promoter of MMP-9 [15].
Since metastasization to distant organs is causative for 90% of all breast cancer
deaths [16], shedding some light on the molecular mechanisms at the basis of this
process is clearly crucial. Herein, we propose morgana as an important player in breast
tumor metastasization, supporting cancer cell invasion mainly by activating NF-kappaB
transcription factor, thus promoting the transcription of prometastatic and
inflammation-related genes.
9. 9
MATHERIALS AND METHODS
Cell culture
All human breast cancer cell lines were purchased from the American Type Culture
Collection (ATCC, Manassas, VA, USA) and propagated and maintained according to
protocols supplied by ATCC. MDA-MB-231 cells were cultured in DMEM, 10% FBS, 5%
PS. MCF-7 cells were cultured in MEM with 10% FBS, 5% PS and 1% Insulin. BT-549
cells were cultured in RPMI 5% PS, 10% FBS, 1% Insulin. MCF10A were cultured as
previously described [17]. Morgana knock-down in MDA-MB-231 and BT-549 was
performed by infecting cells with pGIPZ lentiviral particles expressing two different
morgana shRNAs together with the TurboGFP (Open Biosystems). Empty pGIPZ
lentiviral vector, expressing TurboGFP reporter, was used as control. MCF-7 and MCF-
10 overexpressing morgana were obtained using a pLVX lentiviral vector coding for
mouse morgana.
Antibodies, Reagents and Plasmids
Western blotting was performed using the following antibodies: anti-morgana P1/PP0
[3], actin, ROCK I, MLC2, MMP2, P-IkBα (Tyr42/46) (Santa Cruz Biotechnologies),
phospho-MLC2, PTEN, phospho-AKT, AKT, IkBα, P-IkBα (Ser32/36), IKKβ (Cell
Signaling), vinculin and β-tubulin (Sigma-Aldrich), MMP-9, IL-6 (Abcam). Bovine Serum
(FBS), Fetal Calf Serum (FCS), Penicillin-Streptomycin (PS) and Lipofectamine 2000
were purchased from Invitrogen (Invitrogen). Epidermal Growth Factor (EGF), heparin,
insulin and hydrocortisone were from Sigma (Sigma-Aldrich) and TNFα was from Tocris
10. 10
(Tocris Bioscience). Plasmids p1242-3x-KB-L and 3xAP1pGL3 were purchased from
Addgene, pGL2, pGL3 and pRL-TK from PROMEGA.
Immunofluorescence
Cells grown on coverslips were fixed in PFA for 10 minutes at RT. Cells were then
incubated for 1 hour with the following primary antibodies: mouse anti-morgana
P1/PPO [3], rabbit MMP-9 (Abcam). Primary antibodies were detected by 1-hour
incubation with FITC- or RITC-conjugated secondary antibodies (Invitrogen). Nuclei
were counterstained with DAPI (Sigma-Aldrich).
Protein extraction and Western blot analysis
Cells were lysed in Tris-buffered saline (1% Triton X-100, 10 mM NaF, 1 mM PMSF, 1
mM Na3VO4 and protease and phosphatase inhibitors from Roche). To detect the
phosphorylation of MLC2 cells were lysed with SDS buffer (1% SDS, 60 mM Tris HCl pH
6.8). Samples were analyzed by Western blotting and detected by the
chemiluminescent reagent LiteAblot (Euroclone).
In vivo tumor and metastasis assays
The use of animals was in compliance with the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of Health and was
approved by the Animal Care and Use Committee of University of Torino. 106
MDA-
MB-231 were resuspended in 100 μl of PBS mixed with 100 μl of matrigel and injected
subcutaneously into the left flank of seven-week-old female SCID mice (Charles River
Laboratories, Wilmington, MA). Tumors were measured with a caliper and 4 weeks
11. 11
after injection mice were dissected and tumors were weighted. For experimental
metastasis assays, 5x105
MDA-MB-231 cells (in PBS) were injected into the tail vein of
7-week-old female immunocompetent NSG mice (Charles River Laboratories). Mice
were dissected 4 weeks later and macrometastases were counted at Nikon SMZ1000
stereomicroscope. Spontaneous metastases were evaluated in 7-week-old female
immunocompetent NSG mice injected with 1x106
MDA-MB-231 cells (in PBS) and
dissected 8 weeks later. Macrometastases were counted at Nikon SMZ1000
stereomicroscope. For all metastasis studies, organs were formalin fixed, cut in small
pieces and paraffin embedded, sectioned and haematoxylin and eosin (H&E) stained.
Micrometastases were evaluated on specimens, with an Olympus BH2 microscope, on
at least three different sections.
Cell pellet preparation and Immunohistochemistry
Cells were cultured in 150 mm plates until they reach confluence, then they were
trypsinized and resuspended in culture medium. After being transferred in a 15 ml
tube, cells were fixed in 10% formalin over night. The cell pellet was then washed with
ethanol 75% and paraffin embedded. For immunohistochemical analysis sections were
deparaffinized and permeabilized with TBS 0.1% Triton for 10 minutes. Endogenous
peroxidases were inhibited by incubating sections with 6% H2O2 for 10 minutes.
Antigen retrieval was performed at 98°C for 30 minutes in citrate buffer pH 6. The
sections were then saturated with TBS 3% milk for 30 minutes at RT and then
incubated with the primary antibodies (IL6 1:600; anti-morgana P1/PPO 1:200) diluted
in TBS plus ¼ of the final volume of blocking buffer, for 30 minutes at RT. After rinsing
in PBS, EnVision+ System Labelled Polymer-HRP (Dako) anti-mouse were used to reveal
12. 12
staining. The reaction was developed using a solution of 3-3’-diaminobenzidine and
H2O2 for 2 minutes. The nuclei were finally counterstained with Mayer’s haemalum.
Migration and invasion assays
To measure migration 7.5x104
MDA-MB-231 were seeded in serum-free media in the
upper chambers of cell culture inserts (transwells) with 8.0 μm pore size membrane
(24-well format, Becton Dickinson, NJ). Invasion assays for MDA-MB-231 were
performed using BioCoat TM Matrigel Invasion Chambers with 8.0 μm pore size
membrane (Becton Dickinson). For migration and invasion, the lower chambers were
filled with complete growth media. After 24 h, the migrated cells present on the lower
side of the membrane were fixed in 2.5% glutaraldehyde, stained with 0.1% crystal
violet and photographed using an Olympus IX70 microscope. Migration and invasion
were evaluated by measuring the area occupied by migrated cells using the ImageJ
software. For the wound healing assay, MDA-MB-231 cells were cultured in 6-well
plates. When 90% confluent, cells were starved 24 hours. Then, a wound was
scratched in the center of the cell monolayer by a sterile plastic pipette tip. The debris
was removed by washing with PBS. The wound was photographed at time 0 and after
24 hours at Zeiss microscopy (Carl Zeiss). The percentage of wound closure was
calculated using Axio Vision programme.
Gelatin zymography
For gelatin zymography, conditioned media and total protein extracts were collected
from confluent MDA-MB-231 cells maintained in serum-free media for 24 hours and
processed as described [18]
13. 13
RNA isolation and qRT–PCR
Total RNA was isolated from MDA-MB-231, MCF-7 and MCF10A using Trizol Reagent
(Invitrogen Life Technologies), following the manufacturer’s recommendations. RNA
was reverse transcribed by using Applied Biosystem high capacity cDNA reverse
transcription kit. Gene expression analysis was performed using TaqMan Gene
Expression Assays (Applied Biosystems) on an ABI Prism 7900HT sequence detection
system (Applied Biosystems). We used 18s as the endogenous control throughout all
experimental analysis. Analysis was performed using the Δ-ΔCt method to determine
fold changes. We used gene-specific primers and the Universal Probe Library System
(Roche Applied Sciences, Indianapolis, IN).
Transfection and Luciferase Assay
Plasmids for the Luciferase Assay were purchased from Addgene: p1242-3x-KB-L,
containing 3 NF-kappaB binding sites upstream of the Firefly Luciferase gene and
3xAP1pGL3, containing 3 AP-1 binding sites upstream of the Firefly Luciferase gene.
For the Luciferase Assay 80000 cells were plated on a 24-well plate. 24 hours later,
cells were co-transfected using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s recommendations with 150 ng of pRL-TK Vector (PROMEGA)
containing the Renilla gene, used as a normalizer and internal control, and with 650 ng
of reporter vector (p1242-3x-KB-L or 3xAP1pGL3), or with empty vector pGL2 or pGL3,
respectively (PROMEGA). 24 hours after transfection Dual-Luciferase Reporter Assay
were performed by Glomax instrument (PROMEGA). Results are calculated as fold
14. 14
changes and shown as means of Firefly Luciferase activity normalized on Renilla
luciferase activity.
Statistical significance
The data are presented as means ± s.e.m. In statistical analyses, significance was
tested using a two-tailed Student's t test or, when required, one or two-way ANOVA
with Bonferroni's correction. For all analyses, a minimum value of P<0.05 was
considered significant. All statistical analyses were performed using GraphPad Prism 4
(GraphPad Software version 4.0).
15. 15
RESULTS
Morgana knockdown cells show impaired migration and invasion in vitro
Since we wanted to asses if morgana could play a role in migration and
invasion, we generated MDA-MB-231 cells infected with an empty vector or with two
different shRNA against morgana. We then evaluated the amount of morgana in these
cells by Western Blot and we confirmed that cells transduced with two shRNA showed
a considerable reduction in morgana protein levels (Fig.1A). MDA-MB-231 are highly
metastatic cells, which display a strong ability to migrate and invade. Strikingly,
morgana downregulation in these cells impaired their ability to migrate, assessed both
by wound healing assay and transwell migration assay (Fig. 1B, C). Moreover, we
measured the invasive capacity of MDA-MB-231 infected with shmorgana compared
with control cells, by performing a transwell invasion assay through matrigel.
Interestingly, morgana downregulated MDA-MB-231 displayed a strong reduction of
their invasive capacity, compared to control cells (Fig. 1D). Thus, these results indicate
that morgana downregulation causes an impairment in the migration and invasion
capacity of MDA-MB-231.
Morgana knockdown cells show impaired metastasis formation in vivo
To examine morgana ability to regulate breast cancer cell metastasis formation in vivo,
1x105
MDA-MB-231 cells infected with an empty vector or with a shRNA against
morgana were injected in the tail vein of immuno-deficient NOD/SCID/IL-2Rγc null
(NSG) mice. As expected, control cells efficiently led to macrometastasis formation in
lung, spleen, liver and heart, but no macrometastasis were found in mice receiving
16. 16
cells in which morgana was downregulated (Table 1). We then analyzed the
histological sections of several organs for the presence of micrometastasis: mice
injected with control cells displayed several micrometastasis in all the organs analyzed,
while mice injected with shmorgana MDA-MB-231 displayed few micrometastasis in
the lung (Fig. 2A) but not in other organs. Furthermore, we analyzed by
immunohistochemistry morgana expression in sections of tumors and metastasis
developed by mice inoculated with shmorgana cells, revealing that even the few
micrometastasis developed by these mice presented high morgana levels, comparable
with the one of control cells (Fig. 2B). This evidence suggests that probably these
micrometastasis were induced by escaper cells, which start re-expressing morgana at
high levels again, further supporting the idea that morgana is crucial for
metastasization. To assess morgana ability to promote spontaneous metastasization
from primary tumors, we subcutaneously inoculated 1x106
MDA-MB-231 in the
mammary fat pad of immunodeficient NSG mice. Even in this case, only control cells
gave rise to macrometastasis in the lung (Fig. 2C), thus confirming our previous results.
Moreover, we didn’t find any differences in size and weight of primary tumors (data
not shown), and this is in line with our previous observation that shmorgana cells do
not show an impairment of in vitro proliferation compared to control cells [7], Thus,
morgana role in promoting metastasis formation is to be directly related to an
enhancement of the metastatic ability of cells, and not to proliferation effects.
Morgana downregulation causes a decrease in MMP-9 activity and expression
It is well established that some matrix metalloproteinases such as MMP2 and
MMP-9 play a pivotal role in degrading the extracellular matrix, thus promoting cell
17. 17
invasion. Elevated MMP-9 expression correlates with increased metastatic potential in
a number of tumor types, such as brain, prostate, bladder and breast tumors [12]. For
this reason, we decided to assess the activity and expression of these
metalloproteinases in control and morgana downregulated MDA-MB-231.
Interestingly, shmorgana MDA-MB-231 showed a reduction in the activity of MMP-9,
but not MMP2, both in the intracellular and extracellular compartments, as assessed
by gelatin zymography (Fig. 3A, B). Moreover, we evaluated MMP-9 protein levels,
revealing that morgana downregulated cells have a decreased MMP-9 intracellular and
extracellular protein level, while no significant changes were detectable regarding
MMP2 (Fig. 3C, D). These data have been further confirmed by immunofluorescence
(Fig. 4A, B). In order to assess if morgana is able to control MMP-9 expression not only
at the protein level, but also at the transcriptional level, we performed reverse
transcriptase PCR followed by quantitative Real Time PCR, and we found that morgana
downregulated cells displayed a strong reduction also in MMP-9 mRNA levels (Fig. 4C).
Accordingly, also from the transcriptional point of view MMP2 remains unchanged in
morgana downregulated cells (Fig. 4D), suggesting a specific role for morgana in the
regulation of MMP9 transcription.
Morgana effect on MMP-9 expression is not dependent on ROCK/PTEN/AKT pathway
Our previous works demonstrated that morgana is able to bind and inhibit
ROCKI and II [3] [7] and that through ROCK inhibition morgana downregulates PTEN
expression levels, thus enhancing Akt phosphorylation [7]. Through their action on
cytoskeleton and actinomyocin contractility, Rho kinases play a central role in the
regulation of cell migration and impacts on several components of the metastatic
18. 18
process, including migration, local invasion and cell proliferation [19]. Given that the
PI3K/AKT pathway has been reported to induce cancer cell invasion [20], we tested if
morgana dependent MMP-9 transcription was related to this pathway, by treating
control and shmorgana MDA-MB-231 with the ROCK inhibitor Y27632 and the PTEN
inhibitor vo-ohpic. The activity of the two inhibitors was assessed by Western Blot: as
expected, MDA-MB-231 cells treated with Y27632 showed a decreased
phosphorylation of MLC2, which is a known substrate for ROCK (Fig. 5A), while MDA-
MB-231 treated with vo-hopic showed an increased AKT phosphorylation (Fig. 5B).
Surprisingly, both inhibitors failed to restore normal MMP-9 expression (Fig. 5C, D),
thus indicating that morgana activation of MMP-9 expression is independent on the
ROCK/PTEN/AKT axis.
Morgana regulates MMP-9 expression through NF-kappaB transcription factor
It is known that among the many signals activating MMP-9 expression, most of
them converge on two major transcription factors controlling MMP-9 transcription,
which are AP-1 and NF-kappaB [21] [22]. Therefore, we performed a luciferase assay in
order to understand if morgana could influence the activity of these transcription
factors. We used a NF-κB–responsive reporter plasmid and an AP-1 responsive
reporter plasmid, in which the expression of Firefly luciferase is controlled by a
cassette containing three binding sites for NF-kappaB and AP-1, respectively. We
demonstrated that the activity of AP-1 was unchanged when morgana is
downregulated in MDA-MB-231 (Fig.6A), while on the contrary, the activity of NF-
kappaB significantly decreased in the same cells downregulated for morgana (Fig. 6B).
In order to confirm this result, we generated BT-549 cells infected with an empty
19. 19
vector or with two different shRNA against morgana and we repeated the same
experiment on these cells: again, morgana downregulation could inhibit the activity of
NF-kappaB in these cells (Fig. 6C). In line with these data, NF-kappaB activity increased
when morgana is upregulated in MCF-7 and MCF10A (Fig. 6D, E). Thus, we
demonstrated that morgana is able to regulate NF-kappaB, but not AP-1,
transcriptional activity.
Morgana overexpressing cells show increased expression of NF-kappaB target genes
It is well established that NF-kappaB is a pivotal transcription factor involved in
the regulation of many inflammatory genes such as TNFα, TGFβ, interleukins and
chemokines. Therefore, to further confirm our previous data, we analyzed by qRT-PCR
the expression of some NF-kappaB target genes. As shown in Fig. 7A, shmorgana MDA-
MB-231 cells showed a reduction in MMP-9, IL1α, IL1β, IL6, CCL5 and IL24 mRNA,
compared with control cells. In line with this result, the transcription of some NF-
kappaB dependent genes was upregulated in MCF-7 and in MCF10A cells
overexpressing morgana, upon treatment with TNFα for 4 hours to activate the
transcription of these genes that otherwise is almost completely blocked (Fig. 7B, C).
Eventually, we further confirmed that morgana downregulation can cause a decrease
in IL6 at the protein level: we performed immunohistochemical analysis on cell pellets
of MDA-MB-231 infected with an empty vector of downregulated for morgana, and we
observed that when morgana was downregulated there was a decrease in IL6
production (Fig. 8A). Moreover, we repeated the same experiment on sections of
primary tumors developed by mice injected with MDA-MB-231 infected with an empty
vector or with a shRNA against morgana. As expected, tumors derived from control
20. 20
cells displayed high levels of IL6, while tumors developed by mice injected with cells in
which morgana was downregulated displayed a decrease in the amount of IL6 (Fig. 8B),
confirming the impairment of interleukin 6 production in morgana knockdown cells
also at the protein level.
Morgana modulates NF-kappaB pathway
In order to understand how morgana can affect NF-kappaB activity, we looked at the
protein level of the major player in NF-kappaB pathway. Interestingly, when morgana
is downregulated in MDA-MB-231 there is a decrease in the phosphorylation of IkB on
serine 32 and serine 36 (Fig. 9A). Further confirming this result, morgana
downregulation causes a decrease in the serine phosphorylation of IkB also in BT-549
cells (Fig.9B). Accordingly, when morgana is overexpressed in MCF-7 and in MCF10A,
there is an increase in IkB serine phosphorylation (Fig. 9C, D). To conclude, we
demonstrated that morgana can enhance NF-kappaB activity by increasing the serine
phosphorylation of IkB, but the specific mechanism by which it acts has still to be
elucidated.
21. 21
CONCLUSIONS AND FUTURE PERSPECTIVES
Morgana has been previously characterized as an hsp90 co-chaperone involved
in the control of genomic stability maintenance by regulating the centrosome
duplication via ROCKII kinase. In fact, morgana haploinsufficiency causes multiple
centrosomes, multipolar spindles and increased tumorigenicity induced by chemical
mutagens in mice [3]. Moreover, it has been recently shown that morgana
heterozygous mice develop with age a lethal myeloproliferative disease that resembles
human atypical chronic myeloid leukemia (aCML), preceded by ROCK hyperactivation,
centrosome amplification and aneuploidy [6]. The importance of morgana in
preventing cancer progression is highlighted by the evidence that a consistent fraction
of breast and lung tumors displays low levels of morgana [3]. All these evidences
strongly suggest that morgana acts as a tumor suppressor. However, our tissue array
analysis showed that a small subset of breast and lung tumors overexpresses morgana
[3]. Further analyzing this intriguing result, we demonstrated that morgana
overexpression induces transformation of NIH-3T3 and strongly protects them from
various apoptotic stimuli, such as chemotherapic treatment [7]. In particular, the
mechanism whereby morgana drives cancer progression involves the inhibition of
ROCKI, thus leading to a destabilization of PTEN and a subsequent increase in the
phosphorylation of AKT [7]. Hereby we show a second mechanism with whom
morgana have a pro-tumorigenic role: morgana is able to promote metastasis
formation by activating the NF-kappaB transcription factor. In particular, morgana
overexpressing cells are resistant to anoikis, which is a typical feature of
aggressive/metastatic cancer cells (data not shown). Moreover, morgana
22. 22
downregulation in MDA-MB-231 leads to a consistent decrease in the migration and
invasion of this aggressive cell line. More importantly, MDA-MB-231 downregulated
for morgana lose their ability to give rise to metastasis in NSG mice, both when
subcutaneously and tail vein injected. From a mechanistic point of view, we
demonstrated that morgana downregulated cells possess lower MMP-9 activity, as
assessed by gelatin zymography. MMP-9 is a very well characterized metalloproteinase
that has been associated with metastasis formation in various types of cancers [23].
Moreover, MMP-9 level is reduced both at the protein and at the mRNA levels in
morgana downregulated cells, while no changes are seen in regarding MMP2
metalloproteinase. It has been demonstrated that the PI3K/PTEN/AKT pathway is able
to activate MMP-9 expression, thus favoring metastasis formation in various tumor
types [20]. Nevertheless, morgana dependent activation of MMP-9 expression is not
dependent on this pathway, since nor the ROCK inhibitor (Y27632) nor the PTEN
inhibitor Vo-ohpic are able to revert the phenotype. Instead, interestingly, we
demonstrated that morgana can modulate MMP-9 expression by regulating the NF-
kappaB pathway.
NF-kappaB is a family of transcription factors composed of 5 members: RelA
(also called p65), Rel B, c-Rel, NF-kappaB1 (also called p105) and NF-kappaB2 (also
called p100) [24]. They bind to 9-10 base pair DNA sites with great variability (5’-
GGGRNWYYCC-3’; R = A or G, N = any nucleotide, W = A or T, Y = C or T) and they can
form homodimers or heterodimers with different transcription-modulating properties
[24]. NF-kappaB contributes to the transcription of four main classes of genes: genes
that are involved in negative-feedback control of NF-kappaB itself (such as IKBα, IKBβ,
A20), genes involved in cell proliferation (Cyclin D1, c-Myc), genes that codify for
23. 23
proteins with immunomodulatory functions (chemokines, cytokines, etc.) and anti-
apoptotic genes (BCL-XL, c-FLIP) [25]. Moreover, The NF-kappaB family of transcription
factors plays a pivotal role in both promoting and maintaining an invasive phenotype,
by activating the transcription of genes involved in the epithelial-to-mesenchymal
transition, inflammatory genes and metalloproteinases [26]. In our model, morgana-
dependent NF-kappaB activation leads to increased transcription of several target
genes, including inflammatory genes (IL1α, IL1β, CCL5, IL24, TGFβ, etc.) and
metalloproteinases (MMP-9). Moreover, it should be noticed that NF-kappaB is not
present on MMP2 promoter, thus explaining why we did not see any differences in the
transcription of this metalloproteinase. On the other hand, we did not see any
difference in the transcription of EMT related genes, such as Twist, Snail and Slug (data
not shown). This might be due to the presence of other genetic and epigenetic
mechanisms controlling the transcription of these genes besides morgana, thus
probably morgana alone is not sufficient to induce their transcription is these specific
cellular settings.
There are two main pathways of NF-kappaB activation: the classical pathway
(which concerns RelA, C-Rel and NF-kappaB 1) involves the activation of the IKK
complex (especially IKKβ) which phosphorylates IKB, thus targeting it to ubiquitin-
dependent degradation and subsequent liberation of NF-kappaB dimers that can
translocate to the nucleus and activate the transcription of NF-kappaB-dependent
genes; the alternative activation pathway (which affects NF-kappaB 2 and RelB)
involves activation of IKKα and NIK, inducing phosphorylation-mediated activation of
NF-kappaB 2, that can translocate to the nucleus and activate the transcription [25].
Thus, in the classical activation pathway, IKBα held NF-kappaB in the cytoplasm
24. 24
inhibiting its transcriptional activity, and IKKβ-mediated phosphorylation of IKBα on
two conserved serine residues (S32-S36) leads to its ubiquitination and subsequent
proteasomal degradation [25]. We demonstrated that morgana downregulated cells
have a minor activation of NF-kappaB pathway and, accordingly, morgana
overexpressing cells present an hyperactivation of the NF-kappaB pathway. Moreover,
we found that high morgana levels are combined with higher P-IKBα (on S32/S36).
Another less studied phosphorylation site on IKBα is the tyrosine phosphorylation
(Y42-Y44), which causes NF-kappaB activation without proteolytic degradation of IKBα
[27]. Nevertheless, we show that these alternative sites of phosphorylation on IKBα
are not affected by morgana (data not shown). All things considered, the key evidence
is that morgana overexpression induces an increase, while morgana downregulation
causes an impairment in NF-kappaB transcriptional activity, although the exact
mechanism whereby morgana modulates this pathway and the precise involvement of
IkB degradation is still to be elucidated.
Constitutively activated NF-kappaB transcription factors have been associated
with several aspects of tumorigenesis, including cancer-cell proliferation, apoptosis
prevention, tumor angiogenesis and inflammation, and increased metastatic potential
[28]. In particular, some studies suggests that NF-kappaB activation might be one of
the early events in breast cancer pathogenesis, since it is activated in most human
breast cancer cells, regardless of hormone-dependency status [29]. Moreover, NF-
kappaB activation has been reported to boost metalloproteinase-dependent matrix
destruction by cancer-cells, thus promoting metastasis formation [30]. Among breast
cancer patients the mortality results entirely from invasion and metastasis of cancer
cells in distant organs, and this is true especially for triple-negative breast cancers.
25. 25
Triple negative breast cancers are generally more aggressive than the other subtypes,
with a higher rate of relapse and decreased overall survival in the metastatic disease
[31]. In particular, those patients who achieve pathological complete response to
neoadjuvant chemotherapy have survival rates similar to those of other breast cancer
subtypes. On the other hand, patients who do not respond to standard-of-care
chemotherapy have significantly worse survival and higher rate of relapse within the
first 3 years after treatment [32]. We demonstrated that morgana is expressed with
higher incidence (36%) in triple-negative breast cancer samples, compared with other
subtypes, thus indicating a possible role for morgana in promoting this aggressive
phenotype. Moreover, it is known that NF-kappaB constitutive activation is
characteristic of the basal-like subtype breast-cancer cell lines [33] and this
transcription factor has been associated with increased migration, invasion and
metastatic potential of triple-negative breast cancer cells [34] [21]. Furthermore,
TNBCs are characterized by a high degree of heterogeneity, both inter and intratumor,
and years of studying have failed in finding a single common alteration to be targeted,
thus hindering the development of successful therapeutic strategies [8]. The lack of a
high frequency oncogenic driver is the main cause of the poor outcome of this disease
compared with the other subtypes. Therefore, there is clearly a major need in
understanding the molecular basis of TNBCs and in identifying specific target in order
to develop effective therapeutic strategies. Interestingly, morgana ability to enhance
NF-kappaB transcriptional activity and its enrichment in triple-negative breast cancers
strongly support the idea that morgana is a key player in promoting the aggressive
phenotype of triple-negative breast cancers.
26. 26
It should be noted that morgana is an hsp90 co-chaperone [4]. Hsp90 is a key
component providing maintenance of cellular homeostasis and can interact with two
classes of proteins: more than 200 client proteins whose correct conformation and
activation is promoted by hsp90, and “co-chaperones”, which are accessory proteins
that assist and collaborate with hsp90. Since chaperone proteins are required for
stabilization and activation of numerous client proteins involved in essential cellular
processes like signal transduction pathways, it is possible that morgana modulates the
NF-kappaB pathway through her chaperone activity. Moreover, there are some
evidences showing that hsp90 itself, together with other co-chaperones, is able to
activate the NF-kappaB pathway. In particular, hsp90 and Cdc37, another hsp90 co-
chaperone, are part of the IKK complex and are responsible for its stabilization:
treatment with hsp90 inhibitor Geldanamycin (GA) prevents activation of NF-kappaB,
upon TNFα stimulation [35]. It is likely that the biological significance of IKK complex
regulation by hsp90 and other chaperones is to provide a flexible mechanism to co-
regulate a variety of stress response in collaboration with other signaling pathways,
including immune regulation during heat shock [36]. Considering that, we are planning
to figure out if morgana can interact with the IKK complex together with hsp90 and if
there are differences in the activity of the complex itself upon morgana
downregulation or overexpression, in order to define more clearly morgana role in this
pathway.
Furthermore, another major point that we are planning to do is to evaluate if
morgana expression correlates with NF-kappaB pathway hyperactivation in breast
cancer patients. For instance, we would like to analyze the expression of some NF-
kappaB target genes that we found overexpressed in cells with high morgana levels. In
27. 27
accordance, we show by immunohistochemical analysis that section of primary tumors
developed by mice injected with control cells displayed high levels of IL-6, which is a
well-known target of NF-kappaB, while tumors developed by mice injected with cells in
which morgana was downregulated displayed a decrease in the amount of IL-6.
Furthermore, morgana correlates with tumor grade, lymph node positivity, and
proliferation capacity, which are all characteristics of aggressive tumors [7] and
morgana coding gene was found to be amplified in 19% of basal-like triple negative
breast cancers present in the Cancer Genome Atlas [37]. In accordance, morgana is
overexpressed at higher levels in triple-negative breast cancers (36%) [7] and it is well
known that these cancers are associated with a constitutive activation of the NF-
kappaB pathway: for this reason, we think that morgana will probably correlate with
hyperactivation of this pathway in TNBCs and we propose morgana as a marker for
aggressiveness.
To conclude, we demonstrated that morgana is overexpressed in highly
aggressive tumors and can promote invasion by enhancing MMP-9 expression through
activation of the NF-kappaB transcription factor. Thus, we show that morgana is a key
player in the metastasization process and we propose it as a new biomarker to
guarantee patience survival and precise targeted therapy, especially among triple-
negative breast cancers.
28. 28
ACKNOWLEDGMENTS
I wish to express my sincere thanks to Professor Mara Brancaccio, for passing on her
scientific passion to me and for making me grow not only as a scientist, but also as a
person. Moreover, I would like to thank Professor Guido Tarone, for the support and
guidance and for all the scientific advices. Importantly, my deep appreciation to
Fiorella Altruda and Lorenzo Silengo, for giving me the opportunity to develop my
thesis project at the Molecular Biotechnology Center and for providing me all the
facilities being required.
This work would not have been possible without the continuous and constant help of
my tutor, Federica Fusella, who patiently assisted me in every experiment I performed
and for her sincere and valuable guidance and encouragement. Moreover, I am
grateful to all the members of my group, Stefania, Laura, and Enrico, because of the
great atmosphere that we created together in the lab and for sharing expertise among
each other.
Furthermore, I would like to thank Francesca Orso from Daniela Taverna’s group for
her help with the Luciferase Assay, and to Tiziana Cravero from Emilia Turco’s group,
for the production of our morgana antibody for immunohistochemistry.
Eventually, I take this opportunity to express gratitude to my family and friends, for
economical and emotional support through all these years.
29. 29
REFERENCES
1. Shirasu, K., et al., A novel class of eukaryotic zinc-binding proteins is required for
disease resistance signaling in barley and development in C. elegans. Cell, 1999.
99(4): p. 355-66.
2. Brancaccio, M., et al., Chp-1 and melusin, two CHORD containing proteins in
vertebrates. FEBS Letters, 2003. 551(1-3): p. 47-52.
3. Ferretti, R., et al., Morgana/chp-1, a ROCK inhibitor involved in centrosome
duplication and tumorigenesis. Dev Cell, 2010. 18(3): p. 486-95.
4. Michowski, W., et al., Morgana/CHP-1 is a novel chaperone able to protect cells
from stress. Biochim Biophys Acta, 2010. 1803(9): p. 1043-9.
5. Fukasawa, K., Oncogenes and tumour suppressors take on centrosomes. Nat
Rev Cancer, 2007. 7(12): p. 911-24.
6. Di Savino, A., et al., Morgana acts as an oncosuppressor in chronic myeloid
leukemia. Blood, 2015. 125(14): p. 2245-53.
7. Fusella, F., et al., Morgana acts as a proto-oncogene through inhibition of a
ROCK-PTEN pathway. J Pathol, 2014. 234(2): p. 152-63.
8. Lehmann, B.D. and J.A. Pietenpol, Identification and use of biomarkers in
treatment strategies for triple-negative breast cancer subtypes. J Pathol, 2014.
232(2): p. 142-50.
9. Gupta, G.P. and J. Massague, Cancer metastasis: building a framework. Cell,
2006. 127(4): p. 679-95.
10. Valastyan, S. and R.A. Weinberg, Tumor metastasis: molecular insights and
evolving paradigms. Cell, 2011. 147(2): p. 275-92.
30. 30
11. Oskarsson, T., Extracellular matrix components in breast cancer progression and
metastasis. Breast, 2013. 22 Suppl 2: p. S66-72.
12. Overall, C.M. and O. Kleifeld, Tumour microenvironment - opinion: validating
matrix metalloproteinases as drug targets and anti-targets for cancer therapy.
Nat Rev Cancer, 2006. 6(3): p. 227-39.
13. Egeblad, M. and Z. Werb, New functions for the matrix metalloproteinases in
cancer progression. Nat Rev Cancer, 2002. 2(3): p. 161-74.
14. Coussens, L.M., B. Fingleton, and L.M. Matrisian, Matrix metalloproteinase
inhibitors and cancer: trials and tribulations. Science, 2002. 295(5564): p. 2387-
92.
15. Overall, C.M. and C. Lopez-Otin, Strategies for MMP inhibition in cancer:
innovations for the post-trial era. Nat Rev Cancer, 2002. 2(9): p. 657-72.
16. Imbert, V. et al., Tyrosine Phosphorylation of IkBa Activates NF-kB without
proteolytic degreadation of IkBa. Cell, 1996. 86. p. 787-798.
17. Muthuswamy, S.K., et al., ErbB2, but not ErbB1, reinitiates proliferation and
induces luminal repopulation in epithelial acini. Nat Cell Biol, 2001. 3(9): p. 785-
92.
18. Toth, M. and R. Fridman, Assessment of Gelatinases (MMP-2 and MMP-9 by
Gelatin Zymography. Methods Mol Med, 2001. 57: p. 163-74.
19. Morgan-Fisher, M., U.M. Wewer, and A. Yoneda, Regulation of ROCK activity in
cancer. J Histochem Cytochem, 2013. 61(3): p. 185-98.
20. Park, S.K., et al., Kalopanaxsaponin A inhibits PMA-induced invasion by reducing
matrix metalloproteinase-9 via PI3K/Akt- and PKCdelta-mediated signaling in
MCF-7 human breast cancer cells. Carcinogenesis, 2009. 30(7): p. 1225-33.
31. 31
21. Li, T., et al., Fenofibrate induces apoptosis of triple-negative breast cancer cells
via activation of NF-kappaB pathway. BMC Cancer, 2014. 14: p. 96.
22. Hong, S., et al., Ascochlorin inhibits matrix metalloproteinase-9 expression by
suppressing activator protein-1-mediated gene expression through the ERK1/2
signaling pathway: inhibitory effects of ascochlorin on the invasion of renal
carcinoma cells. J Biol Chem, 2005. 280(26): p. 25202-9.
23. Jacob, A. and R. Prekeris, The regulation of MMP targeting to invadopodia
during cancer metastasis. Front Cell Dev Biol, 2015. 3: p. 4.
24. Gilmore, T.D., Introduction to NF-kappaB: players, pathways, perspectives.
Oncogene, 2006. 25(51): p. 6680-4.
25. Karin, M., et al., NF-kappaB in cancer: from innocent bystander to major culprit.
Nat Rev Cancer, 2002. 2(4): p. 301-10.
26. Min, C., et al., NF-kappaB and epithelial to mesenchymal transition of cancer. J
Cell Biochem, 2008. 104(3): p. 733-44.
27. Imbert, V., et al., Tyrosine phosphorylation of I kappa B-alpha activates NF-
kappa B without proteolytic degradation of I kappa B-alpha. Cell, 1996. 86(5): p.
787-98.
28. Ben-Neriah, Y. and M. Karin, Inflammation meets cancer, with NF-kappaB as
the matchmaker. Nat Immunol, 2011. 12(8): p. 715-23.
29. Cogswell, P.C., et al., Selective activation of NF-kappa B subunits in human
breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene,
2000. 19(9): p. 1123-31.
32. 32
30. Singel, S. M. et al., Receptor-interacting Protein Kinase 2 promotes Triple-
negative Breast Cancer cell migration and invasion via activation of NF-kappaB
and c-Jun N-terminal kinase pathway. Breast Cancer Research. 2014. 16(2): R28
31. Dent, R., et al., Triple-negative breast cancer: clinical features and patterns of
recurrence. Clin Cancer Res, 2007. 13(15 Pt 1): p. 4429-34.
32. Liedtke, C., et al., Response to neoadjuvant therapy and long-term survival in
patients with triple-negative breast cancer. J Clin Oncol, 2008. 26(8): p. 1275-
81.
33. Yamaguchi, N., et al., Constitutive activation of nuclear factor-kappaB is
preferentially involved in the proliferation of basal-like subtype breast cancer
cell lines. Cancer Sci, 2009. 100(9): p. 1668-74.
34. Coussens, M. L. et al., Matrix Metalloproteinase Inhibitors and Cancer: Trials
and Tribulations. 2002. Science. 295. p. 2387-2392.
35. Chen, G., P. Cao, and D.V. Goeddel, TNF-induced recruitment and activation of
the IKK complex require Cdc37 and Hsp90. Mol Cell, 2002. 9(2): p. 401-10.
36. Salminen, A., et al., Innate immunity meets with cellular stress at the IKK
complex: regulation of the IKK complex by HSP70 and HSP90. Immunol Lett,
2008. 117(1): p. 9-15.
37. Cancer Genome Atlas, N., Comprehensive molecular portraits of human breast
tumours. Nature, 2012. 490(7418): p. 61-70.
33. 33
FIGURES AND TABLES
Figure 1
Figure 1. Morgana knockdown cells show impaired migration and invasion in vitro. (A)
Western blot showing morgana downregulation in MDA-MB-231. VINCULIN has been used as a
control. (B) MDA-MB-231 cells infected with an empty vector (EMPTY) or with a shRNA
targeting morgana (shMORG1) were subjected to wound healing assay: representative images
at time points 0 and 24h (on the left); percentage of wound closure after 24 hours, calculated
using the AxioVision program (on the right). (C) Transwell migration assay on EMPTY or
shMORG1 MDA-MB-231 cells. (D) Transwell matrigel invasion assay on MDA-MB-231 infected
with an empty vector (EMPTY) or with two shRNAs targeting morgana (shMORG1, shMORG2).
34. 34
Table 1. Morgana knockdown cells show impaired metastasis formation in vivo. Counts of
micro-metastasis found in organs of NSG mice injected with MDA-MB-231 infected with an
empty vector (EMPTY) or shRNA targeting morgana (ShMORG1).
35. 35
Figure 2
Figure 2. Morgana knockdown cells show impaired metastasis formation in vivo. (A) Tail vein
injection of NSG mice with MDA-MB-231 infected with an empty vector (EMPTY) or with a
shRNA targeting morgana (shMORG). Representative images of hematoxylin stained lung
sections of NSG mice, 1 month after tail vein injection. (B) Representative images of lung
macro and micrometastasis developed by NSG mice 1 month after tail vein injection, stained
for morgana. (C) Metastasis formation 5 weeks after subcutaneous injection of MDA-MB-231
infected with an empty vector (EMPTY) or with a shRNA targeting morgana (shMORG1).
36. 36
Figure 3
Figure 3: Morgana downregulation causes a decrease in MMP-9 activity and expression.
Extracellular (A) and intracellular (B) activity of MMP-9 in MDA-MB-231 infected with an empty
vector (EMPTY) or shRNAs targeting morgana (ShMORG1 and ShMORG2) was evaluated by
gelatin zymography. (A) Top panel: representative zymogram of extracellular MMP-9 activity
(92KDa). Bottom panel: quantification of MMP-9 activity from three independent experiments
(B) Top panel: representative zymogram of intracellular MMP-9 activity (92KDa). Bottom
panel: quantification of MMP-9 activity from three independent experiments. (C) Western blot
analysis of conditioned medium (C.M.) obtained from MDA-MB-231 EMPTY or ShMORG1
immunostained with MMP-9, MMP-2 and hsp90 as loading control. (D) Western blot analysis
of total protein extracts (T.E.) from MDA-MB-231 EMPTY and ShMORG1 immunostained for
MMP9, morgana and vinculin as loading control.
37. 37
Figure 4
Figure 4. Morgana downregulation causes a decrease in MMP-9 activity and expression. (A,
B) Immunofluorescence for MMP-9 (green) (A) and MMP-2 (green) (B) on control (EMPTY) and
morgana downregulated (shMORG) MDA-MB-231 cells. DAPI was used to stain nuclei. (C, D)
RNA was extracted from MDA-MB-231 infected with an empty vector or shRNAs targeting
morgana and real-time PCR analysis was performed to analyze mRNA levels of morgana and
MMP-9 gene (C) and of morgana and MMP-2 gene (D). Results were calculated as fold changes
(mean ± s.e.m.) relative to controls, normalized on 18S.
38. 38
Figure 5
Figure 5. Morgana effect on MMP-9 expression is not dependent on ROCK/PTEN/AKT
pathway. (A) Western blot analysis of VINCULIN, MORGANA, P-MLC2 and total MLC2 on MDA-
MB-231 protein extracts. Cells were infected with an empty vector (EMPTY) or with a shRNA
against morgana (shMORG), and treated with 2µM Y-27632, for 24 hours. (B) Western blot
analysis of VINCULIN, MORGANA, MMP9, P-AKT and total AKT on MDA-MB-231 protein
extracts. Control cells (EMPTY) and morgana downregulated cells (shMORG) were treated with
5µM VO-OHpic, for 30 minutes. (C) RNA was extracted from control and morgana
downregulated MDA-MB-231, untreated or treated with 2µM Y-27632 for 24 hours. Then,
qRT-PCR was performed to analyze MMP9 mRNA. (D) RNA was extracted from control and
morgana downregulated MDA-MB-231, untreated or treated with 5µM VO-OHpic for 24 hours.
Then, qRT-PCR was performed to analyze MMP9 mRNA. Results were calculated as fold-
changes (mean + s.e.m.) relative to controls, and normalized on 18S.
39. 39
Figure 6
Figure 6. Morgana regulates MMP-9 expression through NF-kappaB transcription factor.
(A)Luciferase assay of AP-1 activity on control (EMPTY) and morgana downregulated MDA-MB-
231 cells (shMORG1, shMORG2), transfected with an empty vector (pGL3) or with an AP-1
responsive construct (3x-AP1). (B) Luciferase assay of NF-kappaB activity on control and
morgana downregulated MDA-MB-231 cells, transfected with an empty vector (pGL2) or with
and NF-kappaB responsive construct (3x-kB). (C) Luciferase assay of NF-kappaB activity on
control and morgana downregulated BT-549 cells, transfected with an empty vector (pGL2) or
with and NF-kappaB responsive construct (3x-kB). (D) Luciferase assay of NF-kappaB on control
and morgana overexpressing MCF-7 cells, transfected with an empty vector (pGL2) or with and
NF-kappaB responsive construct (3x-kB). (E) Luciferase assay of NF-kappaB on control (EMPTY)
and morgana overexpressing (OVER MORGANA) MCF10A cells, transfected with an empty
vector (pGL2) or with NF-kappaB responsive construct (3x-kB). All data are presented as fold
changes (mean + s.e.m.) relative to control cells, and normalized to Renilla activity.
40. 40
Figure 7
Figure 7. Morgana overexpressing cells show increased expression of NF-kappaB target
genes. (A) qRT-PCR of MMP-9, CCL-5, IL-1A, IL-1B, IL-6, and IL-24 genes on MDA-MB-231 cells
infected with an empty vector (EMPTY) or with two different shRNA targeting morgana
(shMORG1, shMORG2). (B) qRT-PCR of MMP-9, IL-1A, IL-1B, CCL-5, TGFβ genes on control and
morgana overexpressing MCF-7 cells, untreated or treated (with 10nM TNFα for 4 hours. (C)
qRT-PCR of MMP-9, IL-1A, IL-1B, CCL-5, TGFβ genes on control and morgana overexpressing
MCF-7 cells, untreated or treated with 10nM TNFα for 4 hours.
41. 41
Figure 8
Figure 8. Morgana overexpressing cells show increased expression of NF-kappaB target
genes. (A) Immunohistochemical analysis on cell pellets of control (EMPTY) and morgana
downregulated MDA-MB-231 (shMORG), stained for morgana and IL-6. (B)
Immunohistochemical analysis on sections of primary tumors developed by mice tail vein
injected with control (EMPTY) and morgana downregulated (shMORG) MDA-MB-231, stained
for morgana and IL-6.
42. 42
Figure 9
Figure 9. Morgana regulates the NF-kappaB pathway. (A) Immunoblotting of VINCULIN, P-
IKBα, total IKBα and MORGANA in control (EMPTY) and morgana downregulated (shMORG)
MDA-MB-231 cells. (B) Immunoblotting of VINCULIN, IKKβ, P-IKBα, total IKBα and MORGANA
in control (EMPTY) and morgana downregulated (shMORG) BT-549 cells. (C) Immunoblotting of
VINCULIN, P-IKBα, total IKBα and MORGANA in control (EMPTY) and morgana overexpressing
(MORG) MCF-7 cells. (D) Immunoblotting of VINCULIN, αTUBULIN, P-IKBα, total IKBα and
MORGANA in control (EMPTY) and morgana overexpressing (MORG) MCF10A cells.